Pancreatic and Extrapancreatic Effects of Gastric Inhibitory Polypeptide
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The hormonal factor(s) implicated as transmitters of signals from the gut to pancreatic β-cells is referred to as incretin, and gastric inhibitory polypeptide (GIP) is identified as one of the incretins. GIP is a gastrointestinal peptide hormone of 42 amino acids that is released from duodenal endocrine K-cells after absorption of glucose or fat and exerts its effects by binding to its specific receptor, the GIP receptor. By generating and characterizing mice with a targeted mutation of the GIP receptor gene, we have shown that GIP has not only an insulinotropic role, but also physiological roles on fat accumulation into adipose tissues and calcium accumulation into bone. We here propose a new acronym, GIP, for gut-derived nutrient-intake polypeptide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 5×
“gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide”
BackgroundMethodInfluentialMENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 6×
“gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide”
BackgroundMethodSelf-citationPlasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 5×
“gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide”
BackgroundMethodInfluentialInsulin Action, Diabetogenes, and the Cause of Type II Diabetes
Kahn, C. R. (1994) · Diabetes · doi:10.2337/diab.43.8.1066 · Cited by 916
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 4×
“Islets were incubated with the indicated concentrations of GLP-1(7-36) amide (A) and GIP (B) in the presence of 8.”
BackgroundMethodInfluentialSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 5×
“(24) produced GLP-1 receptor–deficient mice and found that the GLP-1 receptor–deficient mice have mild glucose intolerance accompanied with impaired insulin secretion, especially in the early phase of glucose loading, indicating that GLP-1 also has a physiological role in the regulation of postprandial insulin secreti…”
BackgroundMethodInfluentialCreutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528 · cited 2×
“GIP is secreted from specific endocrine cells (K-cells), which are scattered in the epithelium of the upper part of small intestine (4) after ingestion of a meal (5).”
BackgroundMiyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 7×
“The in vitro perfusion of pancreas and static incubation of islets confirmed that insulin secretions stimulated by glucose in the wildtype and the GIP receptor–deficient mice were comparable (17,18).”
BackgroundMethodSelf-citationFunctional GIP Receptors Are Present on Adipocytes
Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237
Gastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes
Eckel, R. H., Fujimoto, W. Y., & Brunzell, J. D. (1979) · Diabetes · doi:10.2337/diab.28.12.1141 · Cited by 219 · cited 3×
“Furthermore, in vitro studies revealed that GIP stimulates the synthesis and secretion of lipoprotein lipase in rat adipose tissue, which hydrolyzes lipoprotein-associated triglycerides to produce free fatty acids available for local uptake (37).”
BackgroundTsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Bessho, K., Li, M., Amizuka, N., Sato, M., et al. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0187 · Cited by 198
Self-citationPamir, N., Lynn, F. C., Buchan, A. M. J., Ehses, J., Hinke, S. A., Pospisilik, J. A., Miyawaki, K., Yamada, Y., Seino, Y., McIntosh, C. H. S., et al. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00270.2002 · Cited by 126 · cited 5×
“The in vitro perfusion of pancreas and static incubation of islets confirmed that insulin secretions stimulated by glucose in the wildtype and the GIP receptor–deficient mice were comparable (17,18).”
BackgroundMethodSelf-citationEbert, R., Unger, H., & Creutzfeldt, W. (1983) · Diabetologia · doi:10.1007/bf00257346 · Cited by 120 · cited 5×
“gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide”
BackgroundMethodInfluentialSchauder, P., Brown, J. C., Frerichs, H., & Creutzfeldt, W. (1975) · Diabetologia · doi:10.1007/bf00429919 · Cited by 65 · cited 6×
“gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide”
BackgroundMethodInfluential
Cited by
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Self-citationEdfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587
“Thus, apart from directly influencing insulin secretion from -cells via circulating FFAs, Gpr40 may indirectly stimulate GSIS from -cells by modulating the secretion of the incretin hormones GIP and GLP-1 in response to FFAs present in the gastrointestinal lumen (23,24).”
BackgroundThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“Diabetic rats similarly show a selectively impaired insulinotropic response to GIP (660), which indicates that these incretin hormones affect insulin exocytosis with some means for distinction.”
BackgroundInfluentialSeino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Self-citationMusso, G., Gambino, R., Pacini, G., De Michieli, F., & Cassader, M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26720 · Cited by 107
Metadata
- Authors
- Yamada, Y., Miyawaki, K., Tsukiyama, K., Harada, N., Yamada, C., & Seino, Y.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2006-12-01
- Volume
- 55
- Issue
- Supplement_2
- Pages
- S86-S91
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2124251664
- Cited by
- 56
- References
- 18
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.